The strong beat and accelerating CASGEVY revenue should support near-term bullish sentiment. Monitor the CTX310 Phase 1b update at ESC Congress on Aug 28 and the Phase 2 update for CTX611 in H2 2026 for further catalysts.
Price Chart
Executive Summary
CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reached $76M (+151% YoY) and net loss narrowed to $91.2M from $208.5M a year ago. The FDA approval of CASGEVY for children aged 2+ and the advancement of in vivo and siRNA pipeline programs reinforce the company's commercial and clinical momentum.
Key Financial Metrics
Key Facts
- GAAP EPS of -$0.94 beat consensus of -$1.10 (14.5% surprise)
- CASGEVY revenue of $76M in Q2 2026, up 78% QoQ and 151% YoY
- Total revenue of $10.2M vs $0.9M in Q2 2025, driven by collaboration revenue from CASGEVY profit share
- Net loss narrowed to $91.2M from $208.5M in Q2 2025, aided by lower acquired IPR&D expenses
- Cash, cash equivalents, and marketable securities of $2.36B as of June 30, 2026, up from $1.98B at year-end 2025
- FDA approved CASGEVY for children 2+ with SCD or TDT, expanding eligible patient population by ~5,500 patients
- Phase 1 trials initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency)
- Late-breaking abstract on CTX310 (ANGPTL3) accepted at ESC Congress 2026
Financial Impact
EPS beat of 14.5% and CASGEVY revenue growth of 151% YoY are material positive signals for the company's commercial trajectory and pipeline progress.
Risk Factors
- CASGEVY revenue growth depends on reimbursement expansion and patient uptake; Vertex leads commercialization.
- Clinical trial risks for in vivo gene editing and cell therapy programs; early-stage data may not replicate preclinical results.
- Dependence on collaborations (Vertex and Sirius) for key programs; any partnership issues could impact pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.01 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.01 (−1.74%) |
Oct 16, 2026 9d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (−2.06%) |
Oct 16, 2026 9d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (+2.06%) |
Oct 15, 2026 10d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.01 (−0.49%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.01 (−4.87%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.01 (−6.38%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.01 (+9.63%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.01 (−15.09%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.01 (−7.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers